{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:59:35Z","timestamp":1789707575699,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"University of Applied Sciences Darmstadt"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ejmech.2019.111756","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T18:08:14Z","timestamp":1570471694000},"page":"111756","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors"],"prefix":"10.1016","volume":"184","author":[{"given":"Benjamin","family":"Wolff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"J\u00e4nsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisely Oki","family":"Sugiarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Fr\u00fchschulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maraike","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Altintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Oehme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-3249","authenticated-orcid":false,"given":"Franz-Josef","family":"Meyer-Almes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.111756_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.111756_bib2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.2174\/1381612820666141110164604","article-title":"Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer","volume":"21","author":"Kollar","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2019.111756_bib3","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia, Br","volume":"114","author":"Ceccacci","year":"2016","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.ejmech.2019.111756_bib4","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"In cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2019.111756_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.21873\/anticanres.11286","article-title":"Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer","volume":"37","author":"Damaskos","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2019.111756_bib6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ejmech.2018.08.073","article-title":"HDAC as onco target: reviewing the synthetic approaches with SAR study of their inhibitors","volume":"158","author":"Sangwan","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111756_bib7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2019.111756_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","article-title":"Histone deacetylase 8 in neuroblastoma tumorigenesis","volume":"15","author":"Oehme","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2019.111756_bib9","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/pro.2813","article-title":"KDAC8 substrate specificity quantified by a biologically relevant, label-free deacetylation assay","volume":"24","author":"Toro","year":"2015","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2019.111756_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature11316","article-title":"others, HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle","volume":"489","author":"Deardorff","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2019.111756_bib11","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1210\/me.2009-0441","article-title":"An acetylation switch modulates the transcriptional activity of estrogen-related receptor \u2216alpha","volume":"24","author":"Wilson","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejmech.2019.111756_bib12","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1021\/cb500492r","article-title":"An unbiased approach to identify endogenous substrates of \"Histone\" Deacetylase 8","volume":"9","author":"Olson","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2019.111756_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2008.11.135","article-title":"Inactivation of CREB mediated gene transcription by HDAC8 bound protein phosphatase","volume":"379","author":"Gao","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2019.111756_bib14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1128\/MCB.23.2.607-619.2003","article-title":"The inv (16) fusion protein associates with corepressors via a smooth muscle myosin heavy-chain domain","volume":"23","author":"Durst","year":"2003","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejmech.2019.111756_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084015","article-title":"DEC1 coordinates with HDAC8 to differentially regulate TAp73 and DeltaNp73 expression","volume":"9","author":"Qian","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.111756_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nbt.3130","article-title":"Acetylation site specificities of lysine deacetylase inhibitors in human cells","volume":"33","author":"Scholz","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2019.111756_bib17","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2008.9","article-title":"A\u00a0novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas","volume":"22","author":"Balasubramanian","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2019.111756_bib18","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.urolonc.2012.06.015","article-title":"Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers","volume":"31","author":"Niegisch","year":"2013","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejmech.2019.111756_bib19","first-page":"1677","article-title":"Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer","volume":"25","author":"Park","year":"2011","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2019.111756_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.24","article-title":"Selective inhibition of HDAC8 decreases neuroblastoma growth in\u00a0vitro and in\u00a0vivo and enhances retinoic acid-mediated differentiation","volume":"6","author":"Rettig","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2019.111756_bib21","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4155\/fmc-2016-0117","article-title":"Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases","volume":"8","author":"Chakrabarti","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111756_bib22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cmdc.201500486","article-title":"Why hydroxamates may not Be the best histone deacetylase inhibitors-what some may have forgotten or would rather forget?","volume":"11","author":"Shen","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.111756_bib23","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.2174\/092986705774454706","article-title":"Non-hydroxamate histone deacetylase inhibitors","volume":"12","author":"Suzuki","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111756_bib24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.phrs.2018.03.001","article-title":"Structure-activity relationships of HDAC8 inhibitors: non-hydroxamates as anticancer agents","volume":"131","author":"Amin","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2019.111756_bib25","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/cmdc.201600528","article-title":"Histone deacetylase 8 inhibitors","volume":"11","author":"Kleinschek","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2019.111756_bib26","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1039\/C5OB00301F","article-title":"Investigations of possible prodrug structures for 2-(2-mercaptophenyl) tetrahydropyrimidines: reductive conversion from anti-HIV agents with pyrimidobenzothiazine and isothiazolopyrimidine scaffolds","volume":"13","author":"Okazaki","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2019.111756_bib27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbagen.2019.01.001","article-title":"Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine, Biochimica et biophysica acta","volume":"1863","author":"Muth","year":"2019","journal-title":"Gen. Subj."},{"key":"10.1016\/j.ejmech.2019.111756_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1021\/jo902327n","article-title":"Efficient synthesis of pyrimido [1, 2-c][1, 3] benzothiazin-6-imines and related tricyclic heterocycles by SNAr-type C- S, C- N, or C- O bond formation with heterocumulenes","volume":"75","author":"Mizuhara","year":"2009","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2019.111756_bib29","doi-asserted-by":"crossref","first-page":"13554","DOI":"10.1021\/bi801610c","article-title":"Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors","volume":"47","author":"Dowling","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.111756_bib30","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1021\/acs.biochem.5b00010","article-title":"Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8","volume":"54","author":"Decroos","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2019.111756_bib31","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1016\/j.bmc.2011.06.030","article-title":"Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors","volume":"19","author":"Whitehead","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111756_bib32","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.bmcl.2011.01.128","article-title":"On the function of the internal cavity of histone deacetylase protein 8: R37 is a crucial residue for catalysis","volume":"21","author":"Haider","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111756_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41418-018-0080-0","article-title":"A\u00a0kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment","author":"Shen","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2019.111756_bib34","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111756_bib35","first-page":"430","article-title":"Ligand efficiency: a useful metric for lead selection, Drug Discov","volume":"9","author":"Hopkins","year":"2004","journal-title":"Today"},{"key":"10.1016\/j.ejmech.2019.111756_bib36","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1016\/j.bmcl.2013.08.030","article-title":"The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations, Bioorg","volume":"23","author":"Shultz","year":"2013","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2019.111756_bib37","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cell.2010.10.031","article-title":"Sororin mediates sister chromatid cohesion by antagonizing Wapl","volume":"143","author":"Nishiyama","year":"2010","journal-title":"Cell"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419309080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419309080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:01:42Z","timestamp":1759327302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419309080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":37,"alternative-id":["S0223523419309080"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111756","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111756","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111756"}}